<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784875</url>
  </required_header>
  <id_info>
    <org_study_id>12063</org_study_id>
    <secondary_id>I2K-MC-ZZAD</secondary_id>
    <nct_id>NCT00784875</nct_id>
  </id_info>
  <brief_title>An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia</brief_title>
  <acronym>SLUMBER</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients With Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare an investigational drug (LY2624803) with placebo and
      with zolpidem in the treatment of outpatients with chronic insomnia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outpatients with chronic insomnia who participate in this study will be treated in each of
      four 2-week treatment periods with bedtime doses of either placebo, zolpidem, LY2624803 1 mg,
      or LY2624803 3 mg. Neither patients nor investigators will be told what treatments are being
      given in any treatment period. A patient who completes all four treatment periods will be
      treated with placebo in 1, 2, or 3 of the periods; with zolpidem in 0, 1, or 2 of the
      periods; and with LY2624803 in either 1 or 2 of the periods. No patient will receive placebo
      for all four of the 2-week treatment periods. All patients will receive LY2624803 for at
      least one of the four 2-week treatment periods. During each treatment period, patients will
      record information each morning about their sleep the night before, and each evening about
      their functioning since waking up. Patients will also wear wrist actigraphy devices to record
      their physical activity. At the conclusion of each treatment period, patients will answer
      questions about their sleep, functioning, health, and relative preference for treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). Analysis of covariance (ANCOVA) Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unwanted Time Awake at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Unwanted time awake (minutes awake [MA] before sleep [between turning off the lights to first falling asleep], MA during sleep, MA after sleep before getting out of bed). Minimum would be 0; no defined maximum. The higher the number, the more the unwanted time awake. Calculated in minutes from participant-reported daily sleep questionnaire averaged (Avg.) across Period B. Change score subtracts Period B Avg. from Period A Avg. (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group, and insomnia type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Awakenings During Sleep at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Elicited from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Time Awake at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sleep Efficiency at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Calculated as (TIB-TTA)/TIB where TIB is time in bed and TTA is total unwanted time awake. Higher score indicates better sleep efficiency. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Assessment of Sleep Quality at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Assessment of Sleep Quality (ASQ) scale is asked in the participant-reported daily sleep questionnaire; 8 items on 4 point Likert scale with a range of 0 to 24. Sleep experience score ranges from 0-9; awakening experience ranges from 0-15. The higher the score, the better the sleep. Scale is averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participants' Impression of Daytime Functioning Measured by Daily Consequences of Insomnia Questionnaire (DCIQ) at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>DCIQ scale is asked in the participant-reported daily evening questionnaire; 5 point Likert scale with minimum of 0 and maximum of 44 (the higher the score, the more consequences of insomnia). Scale is averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Insomnia Severity Index (ISI) at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>The ISI is a brief self-report instrument that measures a participant's perception of his or her insomnia. 7 questions on 5-point Likert scale with minimum of 0 and maximum of 28. The higher the score, the more severe the insomnia. It was collected at the bi-weekly office visits. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical and Mental Component Scores as Measured by the Short Form 12 (SF-12) Version 2 at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>The SF-12 is a subset of 12 items from the Medical Outcomes Study 36-Item Short Form Survey (SF-36) and was collected at the bi-weekly office visits. Each score ranges from 0-100. The components measure physical and mental health, respectively. Higher scores are indicative of better function. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-related Quality of Life as Measured by European Quality of Life (EuroQol) at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>The EuroQoL Questionnaire-5 Dimension (EQ-5D) is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. The score ranges 0-100. The higher score indicates a better health state perceived by the participant. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction as Measured by the Participant Drug Preference Question</measure>
    <time_frame>Baseline (Period A) and 2 weeks (Period B)</time_frame>
    <description>After study Periods A, and B, participants were asked to rate their experience with the treatment they had just completed. Data are presented as percentage of participants preferring the treatment received in Period A (placebo) or treatment received in Period B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>2 weeks</time_frame>
    <description>Measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much improved) to 7 (very much worse). Data are presented as percentage of participants in each category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint</measure>
    <time_frame>2 weeks</time_frame>
    <description>A scale that measures the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much improved) to 7 (very much worse). Data are presented as percentage of participants in each category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Insomnia Type</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Insomnia Type</measure>
    <time_frame>Baseline through 8 weeks</time_frame>
    <description>Number of participants with AEs and SAEs. Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Age Group</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Age Group</measure>
    <time_frame>Baseline through 8 weeks</time_frame>
    <description>Number of participants with AEs and SAEs. Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline through 8 weeks</time_frame>
    <description>Treatment Emergent Adverse Events (TEAEs) are defined as AEs that first occurred or worsened during the treatment period. TEAEs are summarized by study period and treatment group. TEAEs do not distinguish whether the events were deemed serious. A summary of non-serious AEs is located in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline through 8 weeks</time_frame>
    <description>SAEs do not distinguish whether the events are treatment-emergent. A summary of SAEs is located in the Reported Adverse Event module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure (BP) at Each 2-Week Treatment Endpoint</measure>
    <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
    <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for systolic blood pressure (SBP) and diastolic blood pressure (DBP) are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate at Each 2-week Treatment Endpoint</measure>
    <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
    <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for pulse rate are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight at Each 2-week Treatment Endpoint</measure>
    <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
    <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for body weight are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Analytes at Each 2-Week Treatment Endpoint</measure>
    <time_frame>2 weeks of treatment over 8 weeks</time_frame>
    <description>Summary of number of participants with abnormal clinical chemistry, hematology and urinalysis laboratory results. A participant is included in the abnormal category if he/she experienced a result outside the normal reference ranges based on Lilly's reference range in the current period. All analytes have both lower and upper limits. The abnormal number includes both low (below normal range) and high (above normal range).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint</measure>
    <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
    <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for heart rate are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QT Interval Corrected Using Fridericia Formula (QTcF) as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint</measure>
    <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
    <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTcF is the QT interval corrected for heart rate using Fridericia formula. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>Primary Insomnia</condition>
  <condition>Secondary Insomnia</condition>
  <arm_group>
    <arm_group_label>Period A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2624803</intervention_name>
    <description>1 mg, oral capsule, once nightly before bedtime</description>
    <arm_group_label>Period B</arm_group_label>
    <arm_group_label>Period C</arm_group_label>
    <arm_group_label>Period D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2624803</intervention_name>
    <description>3 mg, oral capsule, once nightly before bedtime</description>
    <arm_group_label>Period B</arm_group_label>
    <arm_group_label>Period C</arm_group_label>
    <arm_group_label>Period D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo (capsule or tablet), once nightly before bedtime</description>
    <arm_group_label>Period A</arm_group_label>
    <arm_group_label>Period B</arm_group_label>
    <arm_group_label>Period C</arm_group_label>
    <arm_group_label>Period D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem</intervention_name>
    <description>5 or 10 mg, oral tablet, once nightly before bedtime</description>
    <arm_group_label>Period B</arm_group_label>
    <arm_group_label>Period C</arm_group_label>
    <arm_group_label>Period D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be between 18 and 85 years of age, with a stable living situation

          -  Clinical diagnosis of either primary insomnia or &quot;secondary&quot; insomnia (comorbid with
             depression, anxiety, and/or medical illness)

          -  Insomnia systems must be at least moderate in severity within the month prior to study
             entry, and must include difficulty staying asleep and/or problems with awakening
             earlier than desired

          -  Psychiatric and medical conditions present must be stable over the 3 months prior to
             study entry, and not expected to worsen significantly or require hospitalization
             during participation in the study

          -  Ongoing treatments for psychiatric and medical conditions present must have been
             stable for the 3 months prior to study entry, and must be expected to remain stable
             during participation in the study

          -  Patients must be willing to abstain from taking medications (other than study drug) to
             help them sleep during participation in the study

          -  Patients must be willing to consistently spend at least 7 hours each night either
             sleeping or trying to sleep during participation in the study

          -  Patients must be able to speak and read English and be capable of using a computer
             with a web browser (computers with internet connections will be provided to patients
             who need them)

        Exclusion Criteria:

          -  Unusual or unstable sleep/wake schedule, such as with rotating shift work

          -  Severe or unstable psychiatric or medical illness

          -  Suicidal ideation

          -  Substance abuse

          -  Known obstructive sleep apnea, restless leg syndrome, or periodic limb movement
             disorder

          -  History of seizures

          -  Body Mass Index &gt; 33

          -  Clinically significant abnormality in clinical chemistry, hematology, urinalysis,
             and/or electrocardiogram

          -  Anticipated inability to regularly use a medication which might reduce motor or
             cognitive functioning during sleeping hours, such as a person who might often need to
             be &quot;on call&quot;, drive a car, or be responsible for the care of another person during
             sleeping hours

          -  Contraindication to zolpidem

          -  History of breast cancer

          -  An estimated glomerular filtration rate (GFR; an index of renal function) that is &lt;30
             mL/min at study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fruitland Park</city>
        <state>Florida</state>
        <zip>34731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wellesley Hills</city>
        <state>Massachusetts</state>
        <zip>02481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <zip>98499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <results_first_submitted>November 17, 2011</results_first_submitted>
  <results_first_submitted_qc>January 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2012</results_first_posted>
  <disposition_first_submitted>December 9, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 15, 2010</disposition_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>LY2624803 was placed on clinical hold by Food and Drug Administration (FDA) on 18 December 2008. The FDA lifted the clinical hold effective 05 May 2009. For analysis purposes, participants who entered into study during 2008 were designated as Cohort 1, whereas participants who entered into study after 2008 were designated as Cohort 2.</recruitment_details>
      <pre_assignment_details>None of Cohort 1 participants completed the study and few progressed beyond Period B. The efficacy analyses were conducted using data from Cohort 2 participants only. Participant flow includes participants from both cohorts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LY2624803 1 mg</title>
          <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
        </group>
        <group group_id="P2">
          <title>LY2624803 3 mg</title>
          <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Zolpidem 5 or 10 mg</title>
          <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received placebo in a 2-week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period A - Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="643"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="461"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="182"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="113"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period B - Efficacy Endpoint</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cohort 2</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period C</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period D</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY2624803 1 mg</title>
          <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
        </group>
        <group group_id="B2">
          <title>LY2624803 3 mg</title>
          <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
        </group>
        <group group_id="B3">
          <title>Zolpidem 5 or 10 mg</title>
          <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received placebo in Period B (2-week treatment period).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="407"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.81" spread="14.07"/>
                    <measurement group_id="B2" value="52.77" spread="14.73"/>
                    <measurement group_id="B3" value="50.65" spread="15"/>
                    <measurement group_id="B4" value="52.86" spread="13.66"/>
                    <measurement group_id="B5" value="52.27" spread="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). Analysis of covariance (ANCOVA) Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). Analysis of covariance (ANCOVA) Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.16" spread="5.300"/>
                    <measurement group_id="O2" value="37.33" spread="5.186"/>
                    <measurement group_id="O3" value="50.63" spread="5.186"/>
                    <measurement group_id="O4" value="22.79" spread="5.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unwanted Time Awake at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Unwanted time awake (minutes awake [MA] before sleep [between turning off the lights to first falling asleep], MA during sleep, MA after sleep before getting out of bed). Minimum would be 0; no defined maximum. The higher the number, the more the unwanted time awake. Calculated in minutes from participant-reported daily sleep questionnaire averaged (Avg.) across Period B. Change score subtracts Period B Avg. from Period A Avg. (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group, and insomnia type.</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unwanted Time Awake at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Unwanted time awake (minutes awake [MA] before sleep [between turning off the lights to first falling asleep], MA during sleep, MA after sleep before getting out of bed). Minimum would be 0; no defined maximum. The higher the number, the more the unwanted time awake. Calculated in minutes from participant-reported daily sleep questionnaire averaged (Avg.) across Period B. Change score subtracts Period B Avg. from Period A Avg. (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group, and insomnia type.</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Sleep (n= 101, 101, 101, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.08" spread="2.524"/>
                    <measurement group_id="O2" value="-6.45" spread="2.444"/>
                    <measurement group_id="O3" value="-20.48" spread="2.440"/>
                    <measurement group_id="O4" value="-1.46" spread="2.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During Sleep (n= 101, 102, 101, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.84" spread="2.881"/>
                    <measurement group_id="O2" value="-12.95" spread="2.812"/>
                    <measurement group_id="O3" value="-21.46" spread="2.819"/>
                    <measurement group_id="O4" value="-8.23" spread="2.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Sleep (n= 100, 101, 99, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.07" spread="2.150"/>
                    <measurement group_id="O2" value="-8.31" spread="2.108"/>
                    <measurement group_id="O3" value="-4.91" spread="2.119"/>
                    <measurement group_id="O4" value="-5.05" spread="2.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Awakenings During Sleep at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Elicited from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Awakenings During Sleep at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Elicited from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>number of awakenings</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.066"/>
                    <measurement group_id="O2" value="-0.26" spread="0.065"/>
                    <measurement group_id="O3" value="-0.59" spread="0.065"/>
                    <measurement group_id="O4" value="-0.18" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Time Awake at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Time Awake at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.63" spread="4.678"/>
                    <measurement group_id="O2" value="-28.62" spread="4.591"/>
                    <measurement group_id="O3" value="-47.28" spread="4.579"/>
                    <measurement group_id="O4" value="-13.09" spread="4.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sleep Efficiency at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Calculated as (TIB-TTA)/TIB where TIB is time in bed and TTA is total unwanted time awake. Higher score indicates better sleep efficiency. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sleep Efficiency at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Calculated as (TIB-TTA)/TIB where TIB is time in bed and TTA is total unwanted time awake. Higher score indicates better sleep efficiency. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.009"/>
                    <measurement group_id="O2" value="0.06" spread="0.009"/>
                    <measurement group_id="O3" value="0.10" spread="0.009"/>
                    <measurement group_id="O4" value="0.03" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Assessment of Sleep Quality at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Assessment of Sleep Quality (ASQ) scale is asked in the participant-reported daily sleep questionnaire; 8 items on 4 point Likert scale with a range of 0 to 24. Sleep experience score ranges from 0-9; awakening experience ranges from 0-15. The higher the score, the better the sleep. Scale is averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Assessment of Sleep Quality at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Assessment of Sleep Quality (ASQ) scale is asked in the participant-reported daily sleep questionnaire; 8 items on 4 point Likert scale with a range of 0 to 24. Sleep experience score ranges from 0-9; awakening experience ranges from 0-15. The higher the score, the better the sleep. Scale is averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.035"/>
                    <measurement group_id="O2" value="0.17" spread="0.034"/>
                    <measurement group_id="O3" value="0.25" spread="0.034"/>
                    <measurement group_id="O4" value="0.13" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling upon Awakening Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.034"/>
                    <measurement group_id="O2" value="0.13" spread="0.033"/>
                    <measurement group_id="O3" value="0.19" spread="0.033"/>
                    <measurement group_id="O4" value="0.12" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Experience Subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.042"/>
                    <measurement group_id="O2" value="0.24" spread="0.042"/>
                    <measurement group_id="O3" value="0.35" spread="0.042"/>
                    <measurement group_id="O4" value="0.15" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participants' Impression of Daytime Functioning Measured by Daily Consequences of Insomnia Questionnaire (DCIQ) at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>DCIQ scale is asked in the participant-reported daily evening questionnaire; 5 point Likert scale with minimum of 0 and maximum of 44 (the higher the score, the more consequences of insomnia). Scale is averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participants' Impression of Daytime Functioning Measured by Daily Consequences of Insomnia Questionnaire (DCIQ) at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>DCIQ scale is asked in the participant-reported daily evening questionnaire; 5 point Likert scale with minimum of 0 and maximum of 44 (the higher the score, the more consequences of insomnia). Scale is averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.395"/>
                    <measurement group_id="O2" value="-0.87" spread="0.385"/>
                    <measurement group_id="O3" value="-1.20" spread="0.394"/>
                    <measurement group_id="O4" value="-0.73" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Insomnia Severity Index (ISI) at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>The ISI is a brief self-report instrument that measures a participant’s perception of his or her insomnia. 7 questions on 5-point Likert scale with minimum of 0 and maximum of 28. The higher the score, the more severe the insomnia. It was collected at the bi-weekly office visits. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Insomnia Severity Index (ISI) at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>The ISI is a brief self-report instrument that measures a participant’s perception of his or her insomnia. 7 questions on 5-point Likert scale with minimum of 0 and maximum of 28. The higher the score, the more severe the insomnia. It was collected at the bi-weekly office visits. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.85" spread="0.587"/>
                    <measurement group_id="O2" value="-2.83" spread="0.578"/>
                    <measurement group_id="O3" value="-4.63" spread="0.582"/>
                    <measurement group_id="O4" value="-1.95" spread="0.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physical and Mental Component Scores as Measured by the Short Form 12 (SF-12) Version 2 at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>The SF-12 is a subset of 12 items from the Medical Outcomes Study 36-Item Short Form Survey (SF-36) and was collected at the bi-weekly office visits. Each score ranges from 0-100. The components measure physical and mental health, respectively. Higher scores are indicative of better function. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary)</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physical and Mental Component Scores as Measured by the Short Form 12 (SF-12) Version 2 at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>The SF-12 is a subset of 12 items from the Medical Outcomes Study 36-Item Short Form Survey (SF-36) and was collected at the bi-weekly office visits. Each score ranges from 0-100. The components measure physical and mental health, respectively. Higher scores are indicative of better function. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary)</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.001"/>
                    <measurement group_id="O2" value="-0.28" spread="0.987"/>
                    <measurement group_id="O3" value="-0.82" spread="0.992"/>
                    <measurement group_id="O4" value="-1.84" spread="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="1.198"/>
                    <measurement group_id="O2" value="1.11" spread="1.181"/>
                    <measurement group_id="O3" value="1.21" spread="1.191"/>
                    <measurement group_id="O4" value="1.94" spread="1.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health-related Quality of Life as Measured by European Quality of Life (EuroQol) at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>The EuroQoL Questionnaire–5 Dimension (EQ-5D) is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. The score ranges 0-100. The higher score indicates a better health state perceived by the participant. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health-related Quality of Life as Measured by European Quality of Life (EuroQol) at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>The EuroQoL Questionnaire–5 Dimension (EQ-5D) is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. The score ranges 0-100. The higher score indicates a better health state perceived by the participant. ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (&lt;65 or ≥65), and insomnia type (primary vs. secondary).</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.06" spread="1.525"/>
                    <measurement group_id="O2" value="-2.56" spread="1.503"/>
                    <measurement group_id="O3" value="-1.71" spread="1.510"/>
                    <measurement group_id="O4" value="0.23" spread="1.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction as Measured by the Participant Drug Preference Question</title>
        <description>After study Periods A, and B, participants were asked to rate their experience with the treatment they had just completed. Data are presented as percentage of participants preferring the treatment received in Period A (placebo) or treatment received in Period B.</description>
        <time_frame>Baseline (Period A) and 2 weeks (Period B)</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction as Measured by the Participant Drug Preference Question</title>
          <description>After study Periods A, and B, participants were asked to rate their experience with the treatment they had just completed. Data are presented as percentage of participants preferring the treatment received in Period A (placebo) or treatment received in Period B.</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period A Treatment (placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="12.6"/>
                    <measurement group_id="O4" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8"/>
                    <measurement group_id="O2" value="77.1"/>
                    <measurement group_id="O3" value="87.4"/>
                    <measurement group_id="O4" value="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Improvement (CGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>Measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much improved) to 7 (very much worse). Data are presented as percentage of participants in each category.</description>
        <time_frame>2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Improvement (CGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>Measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much improved) to 7 (very much worse). Data are presented as percentage of participants in each category.</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 - Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="15.7"/>
                    <measurement group_id="O4" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="34.3"/>
                    <measurement group_id="O4" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="37.3"/>
                    <measurement group_id="O3" value="30.4"/>
                    <measurement group_id="O4" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - Minimally Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint</title>
        <description>A scale that measures the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much improved) to 7 (very much worse). Data are presented as percentage of participants in each category.</description>
        <time_frame>2 weeks</time_frame>
        <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint</title>
          <description>A scale that measures the participant's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much improved) to 7 (very much worse). Data are presented as percentage of participants in each category.</description>
          <population>All randomized Cohort 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 - Very much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="4.2"/>
                    <measurement group_id="O4" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Much improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                    <measurement group_id="O2" value="45.8"/>
                    <measurement group_id="O3" value="55.8"/>
                    <measurement group_id="O4" value="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="15.8"/>
                    <measurement group_id="O4" value="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="4.2"/>
                    <measurement group_id="O4" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - Much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - Very much worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Insomnia Type</title>
        <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>Analyses were not performed by insomnia type because of insufficient number of secondary insomnia patients. Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Insomnia Type</title>
          <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.</description>
          <population>Analyses were not performed by insomnia type because of insufficient number of secondary insomnia patients. Zero participants were analyzed.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Insomnia Type</title>
        <description>Number of participants with AEs and SAEs. Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.</description>
        <time_frame>Baseline through 8 weeks</time_frame>
        <population>Analyses were not performed by insomnia type because of insufficient number of secondary insomnia patients. Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Insomnia Type</title>
          <description>Number of participants with AEs and SAEs. Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.</description>
          <population>Analyses were not performed by insomnia type because of insufficient number of secondary insomnia patients. Zero participants were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Age Group</title>
        <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.</description>
        <time_frame>Baseline, 2 weeks</time_frame>
        <population>Analyses were not performed by age group because of insufficient number of elderly patients. Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in Period B (2-week treatment period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Age Group</title>
          <description>Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.</description>
          <population>Analyses were not performed by age group because of insufficient number of elderly patients. Zero participants were analyzed.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Age Group</title>
        <description>Number of participants with AEs and SAEs. Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.</description>
        <time_frame>Baseline through 8 weeks</time_frame>
        <population>Analyses were not performed by age group because of insufficient number of elderly patients. Zero participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Age Group</title>
          <description>Number of participants with AEs and SAEs. Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.</description>
          <population>Analyses were not performed by age group because of insufficient number of elderly patients. Zero participants were analyzed.</population>
          <units>participants</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAE)</title>
        <description>Treatment Emergent Adverse Events (TEAEs) are defined as AEs that first occurred or worsened during the treatment period. TEAEs are summarized by study period and treatment group. TEAEs do not distinguish whether the events were deemed serious. A summary of non-serious AEs is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline through 8 weeks</time_frame>
        <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAE)</title>
          <description>Treatment Emergent Adverse Events (TEAEs) are defined as AEs that first occurred or worsened during the treatment period. TEAEs are summarized by study period and treatment group. TEAEs do not distinguish whether the events were deemed serious. A summary of non-serious AEs is located in the Reported Adverse Event module.</description>
          <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B (n= 114, 113, 117, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C (n= 103, 97, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D (n= 91, 89, 94, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>SAEs do not distinguish whether the events are treatment-emergent. A summary of SAEs is located in the Reported Adverse Event module.</description>
        <time_frame>Baseline through 8 weeks</time_frame>
        <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>SAEs do not distinguish whether the events are treatment-emergent. A summary of SAEs is located in the Reported Adverse Event module.</description>
          <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure (BP) at Each 2-Week Treatment Endpoint</title>
        <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for systolic blood pressure (SBP) and diastolic blood pressure (DBP) are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
        <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
        <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure (BP) at Each 2-Week Treatment Endpoint</title>
          <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for systolic blood pressure (SBP) and diastolic blood pressure (DBP) are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
          <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B: DBP (n= 112, 111, 117, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.607"/>
                    <measurement group_id="O2" value="0.21" spread="0.610"/>
                    <measurement group_id="O3" value="-0.45" spread="0.594"/>
                    <measurement group_id="O4" value="-0.41" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: SBP (n= 112, 111, 117, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.908"/>
                    <measurement group_id="O2" value="0.91" spread="0.912"/>
                    <measurement group_id="O3" value="-0.05" spread="0.888"/>
                    <measurement group_id="O4" value="-0.37" spread="0.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: DBP (n= 102, 97, 97, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.675"/>
                    <measurement group_id="O2" value="1.11" spread="0.693"/>
                    <measurement group_id="O3" value="-0.68" spread="0.693"/>
                    <measurement group_id="O4" value="-0.51" spread="0.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: SBP (n= 102, 97, 97, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.932"/>
                    <measurement group_id="O2" value="1.54" spread="0.960"/>
                    <measurement group_id="O3" value="0.68" spread="0.957"/>
                    <measurement group_id="O4" value="0.58" spread="0.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: DBP (n= 91, 89, 93, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.751"/>
                    <measurement group_id="O2" value="-0.31" spread="0.760"/>
                    <measurement group_id="O3" value="0.37" spread="0.743"/>
                    <measurement group_id="O4" value="0.75" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: SBP (n= 91, 89, 93, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.097"/>
                    <measurement group_id="O2" value="1.17" spread="1.109"/>
                    <measurement group_id="O3" value="0.87" spread="1.085"/>
                    <measurement group_id="O4" value="2.39" spread="1.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate at Each 2-week Treatment Endpoint</title>
        <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for pulse rate are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
        <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
        <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate at Each 2-week Treatment Endpoint</title>
          <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for pulse rate are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
          <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B (n= 112, 111, 117, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.664"/>
                    <measurement group_id="O2" value="0.95" spread="0.669"/>
                    <measurement group_id="O3" value="0.41" spread="0.653"/>
                    <measurement group_id="O4" value="0.62" spread="0.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C (n= 102, 97, 97, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.758"/>
                    <measurement group_id="O2" value="0.94" spread="0.777"/>
                    <measurement group_id="O3" value="-0.64" spread="0.777"/>
                    <measurement group_id="O4" value="-0.02" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D (n= 91, 89, 93, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.813"/>
                    <measurement group_id="O2" value="-0.36" spread="0.820"/>
                    <measurement group_id="O3" value="1.49" spread="0.803"/>
                    <measurement group_id="O4" value="1.40" spread="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight at Each 2-week Treatment Endpoint</title>
        <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for body weight are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
        <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
        <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Each 2-week Treatment Endpoint</title>
          <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for body weight are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
          <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>kilogram</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B (n= 111, 111, 115, 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.105"/>
                    <measurement group_id="O2" value="0.27" spread="0.105"/>
                    <measurement group_id="O3" value="-0.08" spread="0.103"/>
                    <measurement group_id="O4" value="0.06" spread="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C (n= 104, 100, 97, 96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.129"/>
                    <measurement group_id="O2" value="0.30" spread="0.132"/>
                    <measurement group_id="O3" value="-0.07" spread="0.135"/>
                    <measurement group_id="O4" value="0.09" spread="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D (n=91, 90, 93, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.164"/>
                    <measurement group_id="O2" value="0.17" spread="0.165"/>
                    <measurement group_id="O3" value="0.08" spread="0.162"/>
                    <measurement group_id="O4" value="0.03" spread="0.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Laboratory Analytes at Each 2-Week Treatment Endpoint</title>
        <description>Summary of number of participants with abnormal clinical chemistry, hematology and urinalysis laboratory results. A participant is included in the abnormal category if he/she experienced a result outside the normal reference ranges based on Lilly's reference range in the current period. All analytes have both lower and upper limits. The abnormal number includes both low (below normal range) and high (above normal range).</description>
        <time_frame>2 weeks of treatment over 8 weeks</time_frame>
        <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had endpoint value. For LY2624803 1 mg, LY2624803 3 mg, Zolpidem 5 or 10 mg, and Placebo, the Number of Participants Analyzed were as follows: Period B: N=114, 113,117, 117; Period C: N=103, 97, 97, 98; and Period D: N=91, 89, 94, 88.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Laboratory Analytes at Each 2-Week Treatment Endpoint</title>
          <description>Summary of number of participants with abnormal clinical chemistry, hematology and urinalysis laboratory results. A participant is included in the abnormal category if he/she experienced a result outside the normal reference ranges based on Lilly's reference range in the current period. All analytes have both lower and upper limits. The abnormal number includes both low (below normal range) and high (above normal range).</description>
          <population>All randomized Cohorts 1 and 2 participants who received at least one dose of study drug, and had endpoint value. For LY2624803 1 mg, LY2624803 3 mg, Zolpidem 5 or 10 mg, and Placebo, the Number of Participants Analyzed were as follows: Period B: N=114, 113,117, 117; Period C: N=103, 97, 97, 98; and Period D: N=91, 89, 94, 88.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B: Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Alanine Transaminase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Aspartate Transaminase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Creatine Phosphokinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Glucose, Non-fasting or random</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Blood Urea Nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Leukocyte Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period B: Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Alanine Transaminase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Aspartate Transaminase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Creatine Phosphokinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Glucose, Non-fasting or random</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Blood Urea Nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Leukocyte Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C: Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Alanine Transaminase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Aspartate Transaminase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Creatine Phosphokinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Glucose, Non-fasting or random</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Blood Urea Nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Leukocyte Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D: Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint</title>
        <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for heart rate are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
        <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
        <population>All randomized Cohort 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint</title>
          <description>Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for heart rate are presented. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
          <population>All randomized Cohort 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B (n= 112, 110, 115, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.689"/>
                    <measurement group_id="O2" value="0.26" spread="0.695"/>
                    <measurement group_id="O3" value="1.10" spread="0.681"/>
                    <measurement group_id="O4" value="0.30" spread="0.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C (n= 99, 94, 96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.734"/>
                    <measurement group_id="O2" value="0.31" spread="0.753"/>
                    <measurement group_id="O3" value="-0.02" spread="0.745"/>
                    <measurement group_id="O4" value="1.14" spread="0.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D (n= 91,86, 93, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.827"/>
                    <measurement group_id="O2" value="1.71" spread="0.851"/>
                    <measurement group_id="O3" value="1.43" spread="0.818"/>
                    <measurement group_id="O4" value="0.86" spread="0.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QT Interval Corrected Using Fridericia Formula (QTcF) as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint</title>
        <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTcF is the QT interval corrected for heart rate using Fridericia formula. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
        <time_frame>Baseline, 2 weeks of treatment over 8 weeks</time_frame>
        <population>All randomized Cohort 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2624803 1 mg</title>
            <description>Participants received LY2624803 1 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>LY2624803 3 mg</title>
            <description>Participants received LY2624803 3 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Zolpidem 5 or 10 mg</title>
            <description>Participants received Zolpidem 5 or 10 mg in a 2-week treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo in a 2-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QT Interval Corrected Using Fridericia Formula (QTcF) as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint</title>
          <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. QTcF is the QT interval corrected for heart rate using Fridericia formula. Least Squares Mean (LSMean) values were adjusted for baseline and treatment.</description>
          <population>All randomized Cohort 1 and 2 participants who received at least one dose of study drug, and had both baseline and endpoint values.</population>
          <units>milliseconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period B (n= 112, 110, 115, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="1.314"/>
                    <measurement group_id="O2" value="-2.62" spread="1.325"/>
                    <measurement group_id="O3" value="-1.02" spread="1.300"/>
                    <measurement group_id="O4" value="-1.43" spread="1.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period C (n= 99, 94, 96, 95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="1.335"/>
                    <measurement group_id="O2" value="-0.41" spread="1.373"/>
                    <measurement group_id="O3" value="-3.27" spread="1.356"/>
                    <measurement group_id="O4" value="-3.92" spread="1.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period D (n= 91, 86, 93, 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.319"/>
                    <measurement group_id="O2" value="-2.99" spread="1.344"/>
                    <measurement group_id="O3" value="-3.59" spread="1.293"/>
                    <measurement group_id="O4" value="-1.68" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported for periods B, C, and D. The number of participants at risk vary depending upon the period in which the AE occurred. Due to discontinuations, later periods had fewer participants.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Period B - LY2624803 1 mg</title>
          <description>Patients received LY2624803 1 mg in Period B (2-week treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Period B - LY2624803 3 mg</title>
          <description>Patients received LY2624803 3 mg in Period B (2-week treatment period).</description>
        </group>
        <group group_id="E3">
          <title>Period B - Placebo</title>
          <description>Patients received placebo in Period B (2-week treatment period).</description>
        </group>
        <group group_id="E4">
          <title>Period B - Zolpidem 5 or 10 mg</title>
          <description>Patients received Zolpidem 5 or 10 mg in Period B (2-week treatment period).</description>
        </group>
        <group group_id="E5">
          <title>Period C - LY2624803 1 mg</title>
          <description>Patients received LY2624803 1 mg in Period C (2-week treatment period.</description>
        </group>
        <group group_id="E6">
          <title>Period C - LY2624803 3 mg</title>
          <description>Patients received LY2624803 3 mg in Period C (2-week treatment period).</description>
        </group>
        <group group_id="E7">
          <title>Period C - Placebo</title>
          <description>Patients received placebo in Period C (2-week treatment period).</description>
        </group>
        <group group_id="E8">
          <title>Period C - Zolpidem 5 or 10 mg</title>
          <description>Patients received Zolpidem 5 or 10 mg in Period C (2-week treatment period).</description>
        </group>
        <group group_id="E9">
          <title>Period D - LY2624803 1 mg</title>
          <description>Patients received LY2624803 1 mg in Period D (2-week treatment period.</description>
        </group>
        <group group_id="E10">
          <title>Period D - LY2624803 3 mg</title>
          <description>Patients received LY2624803 3 mg in Period D (2-week treatment period).</description>
        </group>
        <group group_id="E11">
          <title>Period D - Placebo</title>
          <description>Patients received placebo in Period D (2-week treatment period).</description>
        </group>
        <group group_id="E12">
          <title>Period D - Zolpidem 5 or 10 mg</title>
          <description>Patients received Zolpidem 5 or 10 mg in Period D (2-week treatment period).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="117"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="117"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="103"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="97"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="98"/>
                <counts group_id="E8" subjects_affected="42" subjects_at_risk="97"/>
                <counts group_id="E9" subjects_affected="29" subjects_at_risk="91"/>
                <counts group_id="E10" subjects_affected="35" subjects_at_risk="89"/>
                <counts group_id="E11" subjects_affected="25" subjects_at_risk="88"/>
                <counts group_id="E12" subjects_affected="34" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Electrocardiogram t wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dizziness exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E12" events="6" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sleep paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sleep inertia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Uterine spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Postmenopause</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

